Roche culls development of two Huntington’s disease programmes
Roche has stopped development of two of its Huntington’s disease candidates after one failed to show benefit in a Phase…
News
Ipsen set to rival Botox after duo of Phase III migraine wins
Forte Biosciences reports positive results from Phase Ib trial for vitiligo
FDA clears Quoin Pharmaceuticals’ QRX003 IND for Phase II PSS trial
AstraZeneca and Ionis’ stocks drop significantly on Wainua ATTR-CM trial failure
Keenova seeks Xiaflex expansion on late-stage rare disease win
Satellos’ oral DMD drug improves arm movement after six months in Phase II
MAIA reports positive efficacy results from Phase II trial for NSCLC
